Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

SAN DIEGO, Aug. 25 /PRNewswire/ -- NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

DAS181 (Fludase((R))) is an investigational drug candidate in clinical development for Influenza-Like Illness. Unlike neuraminidase inhibitors (e.g. Tamiflu((R))), which target the virus, DAS181 works by inactivating the human host receptor for all influenza and para-influenza viruses tested so far including the current pandemic Novel H1N1 strain ("Swine Flu"). Previous preclinical studies conducted in collaboration with the Centers for Disease Control and Prevention have shown DAS181 to have significant prophylactic and therapeutic activity in an in vivo animal model for a highly virulent H5N1 (A/VN/1203/04) strain of influenza. The current published study, conducted in collaboration with the University of Hong Kong, examined for the first time the effects of DAS181 in human lung tissue and cells. DAS181 strongly inhibited H5N1 (A/VN/3046/2004) infection in human lung tissue and cells. The study also demonstrated that DAS181 effectively removes the two types of sialic acid (Sia) receptors to which influenza virus binds, thereby preventing both the invasion by virus into new cells and further replication where infection already exists.

The human lung tissue and cells described have been critical models for understanding the clinical pathogenesis of influenza, as people contain two types of receptors for influenza. While H5N1 preferentially binds to A2-3-linked Sia, Novel H1N1 preferentially binds to A2-6-linked Sia. DAS181 was shown in these studies to remove both the A2-6-linked and A2-3-linked types found in human respiratory tissue. Most importantly, virus was suppressed by inactivation of the entry receptors by DAS181 treatment.
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Staying true to their mission ... digital product that makes the world a better place, ... Standards Institute (GBSI) to redesign their website ( http://www.gbsi.org ... importantly, strategy-based. , "Biomedical research is not always an ... to promote it in a narrative way on a ...
(Date:4/21/2015)... YORK , April 21, 2015 AbilTo, ... today that its abstract submission has been accepted as ... Association,s (ADA) annual meeting taking place on June 5-6, 2015 ... According to the American Diabetes Association, the cost ... was $245 billion. As a result of increased inpatient, ...
(Date:4/21/2015)... 2015 Invetech , a global ... and contract manufacturing, and  NanoCellect Biomedical, a ... cell sorting technology for life science researchers, today ... cytometry platform. Headquartered in ... a microchip-based cell sorting technology. NanoCellect,s flow cytometry ...
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... , , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ ... TSX: YM), a life sciences product development company that ... products at various stages of development, today reported that ... trial evaluating CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The ...
... , , SEATTLE, Nov. ... Bruce L.A. Carter has joined IDC as Executive Chairman. ... management. He was the former Chief Executive Officer at ... Nordisk, Copenhagen, Denmark. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ...
... , REDWOOD CITY, Calif., Nov. ... therapeutic products for the treatment of chronic respiratory diseases, ... company,s Board of Directors. Mr. Rosen has 25 years ... key roles at Gilead Sciences and ALZA Corporation. His ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... in the brain may unlock the mystery behind the ... issue of Cell. Hibernation allows animals from bears to ... the harshest of winter conditions. , If the findings ... first essential brain signal governing the seasonal adaptation, according ...
... amino acid supplement L-arginine following a heart attack does ... be associated with an increased risk of death, according ... JAMA. , L-arginine is a widely available dietary supplement ... hypertension, angina, heart failure and sexual dysfunction, according to ...
... "biobullet" that could help control an invasive mollusk that ... water pipes, virtually wiping out some native mussels species ... new microcapsules, which contain toxins that dissolve within a ... way of eliminating one of the world's "most important ...
Cached Biology News:Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3Use of amino acid supplement following a heart attack provides no benefit, may be harmful 2'Biobullets' fight harmful mussels 2
...
...
...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Biology Products: